| Company Name: | XenoPort, Incorporated | | Ticker Symbol: | XNPT | | | WWW Address: | www.xenoport.com | | CEO: | Dr. Ronald W. Barrett, Ph.D. | | No. of Employees: | 222 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, which is focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 16.65 |  0.22 | 16.21 | 17.05 | 16.47 | 16.50 | 15.95 | 214292 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 504.5 | 30.3 | 0.76 | -2.48 | 0.00 | 0.0 | 0.0 | 31.92 - 13.36 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 16.43 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 498.5 | mil |
| Latest Shares Outstanding | 30.3 | mil |
| Earnings pS (EPS) | -2.48 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 189,171 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 29.5 | mil |
| Float as % of Shares Outstanding | 97.5 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 83.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 202.60 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.2 | % |
| Return on Assets (ROA) | -38.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -47.5 | % |
| Current Ratio | 10.2 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 4.78 | $ |
| Cash pS | 0.62 | $ |
| Book-Value pS | 4.63 | $ |
| Tangible Book-Value pS | 4.63 | $ |
| Cash Flow pS | -2.14 | $ |
| Free Cash Flow pS | -2.03 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.55 | |
| Price/Tangible Book Ratio | 3.55 | |
| Price/Cash Flow | -7.7 | |
| Price/Free Cash Flow | -8.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.5 | 99 | 3,785 | 7,553 |
| 4 Weeks | 18.55 | 15.13 | 16.71 | -1.7 | 92 | 4,924 | 83,711 |
| 13 Weeks | 25.42 | 15.13 | 17.78 | -7.6 | 86 | 3,660 | 223,262 |
| 26 Weeks | 25.42 | 15.13 | 17.31 | -5.1 | 79 | 3,126 | 390,717 |
| 52 Weeks | 31.92 | 13.36 | 31.44 | -47.7 | 42 | 3,191 | 794,571 |
| YTD | 29.52 | 13.36 | - | -34.5 | 53 | 2,965 | 673,024 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 16.30 | 16.08 | 18.67 | 19.36 | 19.46 | 0.76 | 0.67 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 56.82 | 52.6 | 48.29 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 58.70 | NA | 117.89 |
| R&D | 22.55 | NA | 11.88 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -9.1 | -91.7 | -63.1 |
| Earnings % | 0.0 | 0.0 | -100.0 |
| EPS % | 0.0 | 0.0 | -100.0 |
| EPS $ | 0.04 | 0.15 | -3.56 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 76.19 |
| Current Ratio | 5.8 |
| Quick Ratio (Acid Test) | 5.7 |
| Liquidity Ratio (Cash) | 5.69 |
| Receivables Turnover | 20.6 |
| Average Collection Period | 17 |
| Working Capital/Equity | 105.6 |
| Working Capital pS | 4.72 |
| Cash-Flow pS | -2.25 |
| Free Cash-Flow pS | -1.93 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.72 |
| Financial Leverage Ratio (Assets/Equity) | 1.4 |
| Debt Ratio | 27.9 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 16.6 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.13 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 7.38 |
| Tobin's Q Ratio | 2.95 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -5.93 |
| Enterprise Value (EV)/Free Cash Flow | -7.36 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.55 |
| Price/Book Ratio - LTM | 3.55 |
| Price/Cash Flow Ratio | -7.7 |
| Price/Free Cash Flow Ratio - LTM | -8.1 |
| Price/Sales Ratio | 13.23 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.98 |
| Tangible Book Value pS - LTM | 4.63 |
| Book Value pS - LTM | 4.63 |
| Capital Invested pS | 4.02 |
| Cash pS - LTM | 0.62 |
| Cash Flow pS - LTM | -2.14 |
| Free Cash Flow pS - LTM | -2.03 |
| Earnings pS (EPS) | -2.48 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -125.45 |
| Free Cash Flow Margin 5YEAR AVG | -239.98 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | -95.4 |
| Equity Productivity | 0.34 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.34 |
| Return on Capital Invested (ROCI) | -51.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -56.2 |
| Assets Productivity | 0.20 |
| Return on Assets (ROA) | -37.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -26.8 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -95.3 |
| Effective Tax Rate | 0.6 |
| Effective Tax Rate - 5YEAR AVRG. | 0.6 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 0 |
| Revenue per Employee | 189,171 |
| Net Income per Employee | -281,712 |
| Average Collection Period | 0 |
| Receivables Turnover | 20.6 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 5.38 |
| Assets/Revenue | 5.00 |
| Net Working Capital Turnover | 0.33 |
| Fixed Assets Turnover | 3.14 |
| Total Assets Turnover | 0.2 |
| Revenue per $ Cash | 0.64 |
| Revenue per $ Plant | 3.66 |
| Revenue per $ Common Equity | 0.34 |
| Revenue per $ Capital Invested | 0.34 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 62.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 43.7 |
| Research & Devlopment (R&D) as % of Revenue | 198.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 198.0 |
|
|  
|
| |
 |  |